Antibodies directed to tumor necrosis factor and uses thereof
CA 2508375 C · Owner: Pigott, Craig · Inventors: Lee, Rozanne; Feng, Xiao; Foord, Orit
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antibodies directed to the antigen TNFa and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFa. Nucleotide sequences encoding, and amino acid sequences comprising heavy and , light chain immunoglobulin molecules particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's) specifically from FR1 , through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 2, 2003 and granted May 27, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.